Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial

BACKGROUND: Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now standard first-line therapy. However, the majority of patients relapse and requir...

Descripción completa

Detalles Bibliográficos
Autores principales: Collett, Laura, Howard, Dena R., Munir, Talha, McParland, Lucy, Oughton, Jamie B., Rawstron, Andy C., Hockaday, Anna, Dimbleby, Claire, Phillips, David, McMahon, Kathryn, Hulme, Claire, Allsup, David, Bloor, Adrian, Hillmen, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568356/
https://www.ncbi.nlm.nih.gov/pubmed/28830517
http://dx.doi.org/10.1186/s13063-017-2138-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568356/
https://www.ncbi.nlm.nih.gov/pubmed/28830517
http://dx.doi.org/10.1186/s13063-017-2138-6

Ejemplares similares